RecruitingNCT07093528

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

CMR Substudy of Coronary Sinus Reducer for the Management of Symptomatic Heart Failure With a Preserved Ejection Fraction (HFpEF) Associated With Coronary Microvascular Dysfunction (CMD)


Sponsor

Mayo Clinic

Enrollment

25 participants

Start Date

Oct 16, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Age ≥18
  • Enrollment in main CS-reducer HFPEF study IRB# 25-002292

Exclusion Criteria2

  • Metal implants that are not suitable for MRI
  • Inability or unwillingness of individual to give written informed consent.

Interventions

DIAGNOSTIC_TESTCardiovascular Magnetic Resonance (CMR)

Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR.


Locations(1)

Mayo Clinic

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07093528


Related Trials